Business Development

 

ERYtech Pharma strategy is to develop high value products, targeting hospital markets with more than one € billion potential.

ERYtech Pharma is opened to discuss partnership opportunities with pharma/biotech companies dealing with:

  • its own proprietary products 
  • its technological platform


On technological platform, ERYtech is opened to conduct R&D feasibility study on shared cost basis which will lead to co-development agreement in case of success

A wide variety of compounds between 500 Da and up to 2000 kDa can be encapsulated.

The realization, in house, of a new proof of concept is fast and very cost effective:

- 3 to 6 months, for in vitro POC in human or mice red cells

- 6 to 9 months, for in vivo POC in mice

 

Co-development opportunities:

ERYtech Pharma welcomes partnership discussions on:

  • Therapeutic proteins eliciting inhibitors or neutralizing antibodies or   Proteins/antigens/peptides eliciting autoimmune diseases to develop Immune Tolerance Induction (Gr-Tol program)
  • Antigens/adjuvants to develop active immunotherapies (Gr-Vax program)
  • Compounds with anti-inflammatory properties to innovative therapeutics in the fields of inflammatory or autoimmune diseases, infectious diseases (Immuno-Inflammation application)

For more information on products and submit partnership opportunity, please send an email to busdev@erytech.com

 

Where to meet us:
 

September 14, Philadelphia, PA, USA

September 15-17, Boston, MA, USA

October 10-13, Jerusalem, Israel 
 

 

ERYtech Pharma was awarded from the Rhône-Alpes Ouest Créalys business incubator.
www.crealys.com

 

ERYtech Pharma is granted by the European Commission (FEDER, European Regional Development Fund – ERDF) and the Rhone-Alpes Region (Innovative and International Development – IDéclic Stratégie Fund).

 

Erytech Pharma
Last Update 01/09/2010
2005 ERYtech Inc. All Rights Reserved | Terms and Conditions | Contact Us